经济观察网消息,康乃德生物近期在研发和融资上均有进展。医管攻略2026年2月4日报道,其主要候选药物CBP-307(用于治疗多发性硬化症、炎症性肠病等自身免疫疾病)已完成I期临床试验,即将进入II期,这是其研发管线关键进展。资金方面,2026年2月初,康乃德完成2500万美元A轮融资,由启明创投领投,北极光创投等跟投,资金将用于加速创新药物管线开发,包括CBP-307、CBP-174等临床阶段项目...
Source Link经济观察网消息,康乃德生物近期在研发和融资上均有进展。医管攻略2026年2月4日报道,其主要候选药物CBP-307(用于治疗多发性硬化症、炎症性肠病等自身免疫疾病)已完成I期临床试验,即将进入II期,这是其研发管线关键进展。资金方面,2026年2月初,康乃德完成2500万美元A轮融资,由启明创投领投,北极光创投等跟投,资金将用于加速创新药物管线开发,包括CBP-307、CBP-174等临床阶段项目...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.